(Press-News.org) Contact information: Brian Lin
brian.lin@ubc.ca
604-822-2234
University of British Columbia
UBC-VCH scientists use drug to repair rare birth defect
Success in mouse model is first instance of drug reversing a congenital deformity
University of British Columbia and Vancouver Coastal Health scientists
have developed a potential cure for a rare eye disease, showing for the first
time that a drug can repair a birth defect.
They formulated the drug Ataluren into eye drops, and found that it consistently restored normal vision in mice who had aniridia (ANN-uh-ridee-
uh), a condition that severely limits the vision of about 5,000 people in
North America. A small clinical trial with children and teens is expected to
begin next year in Vancouver, the U.S. and the U.K.
Aniridia is caused by the presence of a "nonsense mutation" – an extra "stop
sign" on the gene that interrupts production of a protein crucial for eye
development. Aniridia patients don't have an iris (the coloured ring around
the pupil), and suffer many other eye abnormalities.
Ataluren is believed to have the power to override the extra stop sign, thus
allowing the protein to be made. The UBC-VCH scientists initially thought
the drug would work only in utero – giving it to a pregnant mother to
prevent aniridia from ever arising in her fetus. But then they gave their
specially formulated Ataluren eye drops, which they call START, to two-week-old mice with aniridia, and found that it actually reversed the damage
they had been born with.
"We were amazed to see how malleable the eye is after birth," said Cheryl Gregory-Evans, associate professor of ophthalmology and visual sciences and a neurobiologist at the Vancouver Coastal Health Research Institute. "This holds promise for treating other eye conditions caused by nonsense mutations, including some types of macular degeneration. And if it reverses damage in the eye, it raises the possibility of a cure for other congenital disorders. The challenge is getting it to the right place at the right time."
A video about the study is available at http://youtu.be/L9Gx1bUxCUg.
BACKGROUND | A POTENTIAL CURE FOR ANIRIDIA
Bad vision at birth, worse vision later: Aniridia is apparent at birth because of the missing iris. Toddlers with aniridia need eyeglasses to see, sunglasses or darkened contact lenses to protect their eyes from overexposure to light, and cannot read small text. Their eyes are continually moving, making it difficult for them to focus, and have higher internal pressure (glaucoma), which damages the optic nerve as they get older. They are also prone to corneal damage in their teens and early adulthood. Eventually, most people with aniridia are considered legally blind, and must resort to Braille or expensive electronic aids to read.
The plasticity of the eye: The reversal of tissue damage in young mice,
published online today by the Journal of Clinical Investigation, fits with the
fact that mammals' eyes aren't fully formed at birth. Human babies don't
discern colours until they are six months old, and their depth perception
isn't fully developed until the age of five.
Nonsense suppressor: Ataluren, made by the New Jersey-based PTC Therapeutics, is thought to be a "nonsense suppressor" – it silences the extra "stop codon" on the gene and allows a complete protein to be assembled. The drug is currently being tested as a treatment for cystic fibrosis and Duchenne muscular dystrophy, which are also caused by nonsense
mutations.
A gritty solution: Gregory-Evans' first attempt at creating Ataluren eye
drops proved unsuccessful. The drug didn't dissolve, and thus irritated the
mice's eyes. So she turned to Kishor Wasan, a professor and associate dean
in the Faculty of Pharmaceutical Sciences, who ground the drug into a very fine powder and combined it with a solution that adhered better to the eye.
A multidisciplinary team: Gregory-Evans also collaborated with her
husband, Kevin Gregory-Evans, the Julia Levy BC Leadership Chair in
Macular Research and an ophthalmologist at the VCH Eye Care Centre, who treats B.C. patients with aniridia. He administered the vision tests for the mice used in the study.
Clinical trial: The forthcoming clinical trial, involving about 30 patients,
will be led by Gregory-Evans in Vancouver, and is being supported by the Vision for Tomorrow Foundation, a U.S.-based charity focused on aniridia
and albinism (an absence of pigmentation in skin, hair and eyes that results in poor vision). If START is proven to be safe and effective, children with aniridia would use the drops twice a day for the rest of their lives. The drug would probably not reverse the condition in adults because their eyes would already be damaged beyond repair.
INFORMATION:
Funding from a UBC alumna: Cheryl Gregory-Evans' position and this
research were funded by the Sharon Stewart Testamentary Trust. Stewart, of Victoria, was born with aniridia, and at the time of her graduation from
UBC in 1968, she only had five per cent of her vision. She died in 2008 and
donated over $6 million to UBC for aniridia research.
UBC-VCH scientists use drug to repair rare birth defect
Success in mouse model is first instance of drug reversing a congenital deformity
2013-12-20
ELSE PRESS RELEASES FROM THIS DATE:
Enlisting cells' protein recycling machinery to regulate plant products
2013-12-20
Enlisting cells' protein recycling machinery to regulate plant products
New molecular tools for controlling production of compounds important for flavors, human health, and biofuels
UPTON, NY--Scientists at the U.S. Department of Energy's Brookhaven ...
New mechanism that permits selective capture of microRNAs in nanovesicles that shuttle between cells
2013-12-20
New mechanism that permits selective capture of microRNAs in nanovesicles that shuttle between cells
The study presents the first description of a set of related nuceleotide sequences essential for the role of these small molecules in ...
More mentions in the FT linked to greater popularity of stocks
2013-12-20
More mentions in the FT linked to greater popularity of stocks
A 6-year study of the Financial Times has found that the more frequently a company is mentioned in the newspaper in the morning, the greater the volume of shares traded in that company during the ...
Efforts to curb climate change require greater emphasis on livestock
2013-12-20
Efforts to curb climate change require greater emphasis on livestock
CORVALLIS, Ore. – While climate change negotiators struggle to agree on ways to reduce carbon dioxide (CO2) emissions, they have paid inadequate attention to other greenhouse gases associated ...
Birth of black hole kills the radio star
2013-12-20
Birth of black hole kills the radio star
Research clears telescope, disproves long-held theory
Astronomers led by a Curtin University researcher have discovered a new population of exploding stars that "switch off" their radio transmissions before collapsing ...
An earthquake or a snow avalanche has its own shape
2013-12-20
An earthquake or a snow avalanche has its own shape
However, it is crucial what one observes – paper fracture or the avalanching of snow. The results were just published in the Nature Communications journal.
Avalanches of snow or earthquakes can be described in other ...
Smooth or grainy?
2013-12-20
Smooth or grainy?
A SISSA paper reviews research on the grain of space-time
Smooth" or grainy? Is space-time continuous or is it made up of very fine (10-35 metres on the "Planck scale") but discrete grains, if we look at it very ...
IRB develops ChroGPS, a new generation visual browser of the epigenome
2013-12-20
IRB develops ChroGPS, a new generation visual browser of the epigenome
This is a software application that provides easily interpretable maps from which to analyse and understand the immense volume of epigenetic and genetic ...
Birth control at the zoo
2013-12-20
Birth control at the zoo
Vets meet the elusive goal of hippo castration
Common hippopotami (Hippopotamus amphibius) are vulnerable to extinction in the wild, but reproduce extremely well under captive breeding conditions. Females ...
Breaking down cancer's defense mechanisms
2013-12-20
Breaking down cancer's defense mechanisms
A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers.
The method uses a drug which breaks down the ...
LAST 30 PRESS RELEASES:
Fig trees convert atmospheric CO2 to stone
Intra-arterial tenecteplase for acute stroke after successful endovascular therapy
Study reveals beneficial microbes that can sustain yields in unfertilized fields
Robotic probe quickly measures key properties of new materials
Climate change cuts milk production, even when farmers cool their cows
Frozen, but not sealed: Arctic Ocean remained open to life during ice ages
Some like it cold: Cryorhodopsins
Demystifying gut bacteria with AI
Human wellbeing on a finite planet towards 2100: new study shows humanity at a crossroads
Unlocking the hidden biodiversity of Europe’s villages
Planned hydrogen refuelling stations may lead to millions of euros in yearly losses
Planned C-sections increase the risk of certain childhood cancers
Adults who have survived childhood cancer are at increased risk of severe COVID-19
Drones reveal extreme coral mortality after bleaching
New genetic finding uncovers hidden cause of arsenic resistance in acute promyelocytic leukemia
Native habitats hold the key to the much-loved smashed avocado’s future
Using lightning to make ammonia out of thin air
Machine learning potential-driven insights into pH-dependent CO₂ reduction
Physician associates provide safe care for diagnosed patients when directly supervised by a doctor
How game-play with robots can bring out their human side
Asthma: patient expectations influence the course of the disease
UNM physician tests drug that causes nerve tissue to emit light, enabling faster, safer surgery
New study identifies EMP1 as a key driver of pancreatic cancer progression and poor prognosis
XPR1 identified as a key regulator of ovarian cancer growth through autophagy and immune evasion
Flexible, eco-friendly electronic plastic for wearable tech, sensors
Can the Large Hadron Collider snap string theory?
Stuckeman professor’s new book explores ‘socially sustainable’ architecture
Synthetic DNA nanoparticles for gene therapy
New model to find treatments for an aggressive blood cancer
Special issue of Journal of Intensive Medicine analyzes non-invasive respiratory support
[Press-News.org] UBC-VCH scientists use drug to repair rare birth defectSuccess in mouse model is first instance of drug reversing a congenital deformity